Snailase Preparation of Ginsenoside M1 from Protopanaxadiol-Type Ginsenoside and Their Protective Effects Against CCl4-Induced Chronic Hepatotoxicity in Mice

To investigate the protective effects of protopanaxadiol-type ginsenoside (PDG) and its metabolite ginsenoside M1 (G-M1) on carbon tetrachloride (CCl4)-induced chronic liver injury in ICR mice, we carried out conversion of protopanaxadiol-type ginsenosides to ginsenoside M1 using snailase. The optimum time for the conversion was 24 h at a constant pH of 4.5 and an optimum temperature of 50 °C. The transformation products were identified by high-performance liquid chromatography and electrospray ion-mass spectrometry. Subsequently, most of PDG was decomposed and converted into G-M1 by 24 h post-reaction. During the study on hepatoprotective in a mice model of chronic liver injury, PDG or G-M1 supplement significantly ameliorated the CCl4-induced liver lesions, lowered the serum levels of select hepatic enzyme markers (alanine aminotransferase, ALT, and aspartate aminotransferase, AST) and malondialdehyde and increased the activity of superoxide dismutase in liver. Histopathology of the liver tissues showed that PDG and G-M1 attenuated the hepatocellular necrosis and led to reduction of inflammatory cell infiltration. Therefore, the results of this study show that PDG and G-M1 can be proposed to protect the liver against CCl4-induced oxidative injury in mice, and the hepatoprotective effect might be attributed to amelioration of oxidative stress

Bupropion hydro­bromide propanol hemisolvate

The title compound {systematic name: N-[1-(3-chloro­phen­yl)-1-oxopropan-2-yl]-tert-butanaminium bromide propanol hemisolvate}, C13H19ClNO+·Br−·0.5C3H8O, crystallizes with two independent bupropion hydro­bromide ion pairs and a solvent 1-propanol mol­ecule in the asymmetric unit. In both mol­ecules, the expected proton transfer from HBr to the amino group of the bupropion mol­ecule is observed, and intra- and inter­molecular N—H⋯Br hydrogen-bond inter­actions are formed. These inter­actions link the mol­ecules into hydrogen-bond dimers. The side chains of the two cations have slightly different orientations. The 1-propanol solvent mol­ecule is linked to a bromide ion by an O—H⋯Br hydrogen bond

Triamcinolone acetonide acetate

In the crystal structure of the title compound [systematic name: 2-(4b-fluoro-5-hy­droxy-4a,6a,8,8-tetra­methyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodeca­hydro-7,9-dioxa­penta­leno[2,1-a]phenanthren-6b-yl)-2-oxoethyl acetate], C26H33FO7, the mol­ecules are connected by inter­molecular O—H⋯O hydrogen bonds into an infinite supra­molecular chain along the b axis. The mol­ecular framework consists of five condensed rings, including three six-membered rings and two five-membered rings. The cyclo­hexa-2,5-dienone ring is nearly planar [maximum deviation = 0.013 (3) Å], while the cyclo­hexane rings adopt chair conformations. The two five-membered rings, viz. cyclo­pentane and 1,3-dioxolane, display envelope conformations

Hederagenin from the leaves of ivy (Hedera helix L.) induces apoptosis in human LoVo colon cells through the mitochondrial pathway

BACKGROUND: Colorectal cancer has become one of the leading cause of cancer morbidity and mortality throughout world. Hederagenin, a derivative of oleanolic acid isolated from the leaves of ivy (Hedera helix L.), has been shown to have potential anti-tumor activity. The study was conducted to evaluate whether hederagenin could induce apoptosis of human colon cancer LoVo cells and explore the possible mechanism. METHODS: MTT assay was used for evaluating cell viability while Annexin V-FITC/PI assay and Hoechst 33342 nuclear stainining were used for the determination of apoptosis and mitochondrial membrane potential. DCFH-DA fluorescence staining and flow cytometry were used to measure ROS generation. Real-time PCR and western blot analysis were performed for apoptosis-related protein expressions. RESULTS: MTT assay showed that hederagenin could significantly inhibit the viability of LoVo cells in a concentration-dependent and time-dependent manner by IC(50) of 1.39 μM at 24 h and 1.17 μM at 48 h. The apoptosis ratio was significantly increased to 32.46% and 81.78% by the induction of hederagenin (1 and 2 μM) in Annexin V-FITC/PI assay. Hederagenin could also induce the nuclear changes characteristic of apoptosis by Hoechst 33342 nuclear stainining under fluorescence microscopy. DCFH-DA fluorescence staining and flow cytometry showed that hederagenin could increase significantly ROS generation in LoVo cells. Real-time PCR showed that hederagenin induced the up-regulation of Bax and down-regulation of Bcl-2, Bcl-xL and Survivin. Western blotting analysis showed that hederagenin decreased the expressions of apoptosis-associated proteins Bcl-2, procaspase-9, procaspase-3, and polyADP- ribosepolymerase (PARP) were increased, while the expressions of Bax, caspase-3, caspase-9 were increased. However, there was no significant change on caspase-8. CONCLUSIONS: These results indicated that the disruption of mitochondrial membrane potential might contribute to the apoptosis of hederagenin in LoVo cells. Our findings suggested that hederagenin might be a promising therapeutic candidate for human colon cancer

High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial

Objectives: To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA). Methods: In this multicenter, randomized and parallel treatment trial, 346 patients with active RA (disease activity score (28 joints) [DAS28] (erythrocyte sedimentation rate [ESR]) > 5.1) were enrolled from 9 centers. In phase 1, patients received intensive treatment with methotrexate, leflunomide, and hydroxychloroquine, up to 36 weeks, until remission (DAS28 ≤ 2.6) or a low disease activity (2.6 < DAS28 ≤ 3.2) was achieved. In phase 2, patients achieving remission or low disease activity were followed up with randomization to 1 of 2 step-down protocols: leflunomide plus hydroxychloroquine combination or leflunomide monotherapy. The primary endpoints were good European League Against Rheumatism (EULAR) response (DAS28 (ESR) < 3.2 and a decrease of DAS28 by at least 1.2) during the intensive treatment and the disease state retention rate during step-down maintenance treatment. Predictors of a good EULAR response in the intensive treatment period and disease flare in the maintenance period were sought. Results: A good EULAR response was achieved in 18.7%, 36.9%, and 54.1% of patients at 12, 24, and 36 weeks, respectively. By 36 weeks, 75.4% of patients achieved good and moderate EULAR responses. Compared with those achieving low disease activity and a high health assessment questionnaire (HAQ > 0.5), patients achieving remission (DAS28 ≤ 2.6) and low HAQ (≤ 0.5) had a significantly higher retention rate when tapering the DMARDs treatment (P = 0.046 and P = 0.01, respectively). There was no advantage on tapering to combination rather than monotherapy. Conclusions: Remission was achieved in a proportion of patients with RA receiving prolonged intensive DMARD therapy. Low disease activity at the start of disease taper leads to less subsequent flares. Leflunomide is a good maintenance treatment as single treatment

Interpretable Foreground Object Search As Knowledge Distillation

This paper proposes a knowledge distillation method for foreground object search (FoS). Given a background and a rectangle specifying the foreground location and scale, FoS retrieves compatible foregrounds in a certain category for later image composition. Foregrounds within the same category can be grouped into a small number of patterns. Instances within each pattern are compatible with any query input interchangeably. These instances are referred to as interchangeable foregrounds. We first present a pipeline to build pattern-level FoS dataset containing labels of interchangeable foregrounds. We then establish a benchmark dataset for further training and testing following the pipeline. As for the proposed method, we first train a foreground encoder to learn representations of interchangeable foregrounds. We then train a query encoder to learn query-foreground compatibility following a knowledge distillation framework. It aims to transfer knowledge from interchangeable foregrounds to supervise representation learning of compatibility. The query feature representation is projected to the same latent space as interchangeable foregrounds, enabling very efficient and interpretable instance-level search. Furthermore, pattern-level search is feasible to retrieve more controllable, reasonable and diverse foregrounds. The proposed method outperforms the previous state-of-the-art by 10.42% in absolute difference and 24.06% in relative improvement evaluated by mean average precision (mAP). Extensive experimental results also demonstrate its efficacy from various aspects. The benchmark dataset and code will be release shortly.Comment: This paper will appear at ECCV 202